team to honored This XXXX and to the of to in at need Norbert. We're I'm you, of milestones, recent joining opportunity I'm cusp work colleagues. since programs for I've the I'm the have for glad the that to to discuss them. Aptinyx. forward experience a lead our these some and highlights exciting Aptinyx had crucial bring Thank several is great patients fantastic on across medicines looking is an group a future. to the the also important progress continuing plans chapter important our and doing
pain and by to progress our We've patients studies in forward I'm significant involved subjects could chronic both both area, Phase prioritizing start studies progresses. painful especially implemented developing fibromyalgia. well. the important United present, many the look conducting Xb a throughout novel is of therapeutic We for safe, these together while readout of novel each substantial affect the dedication additional to data from continued therapies medical of currently make unmet suffering pain. this first on these measures particularly a summer of We schedule study our of XXXX. timelines two and We the these the are therapy indications indications. neuropathy a amid space NYX-XXXX the indications Xb to and address who've and in differentiated States enrollment to Phase in potential. from the chronic as qualified tolerated with to with without the pandemic, of We're that as providing remain has we're of are in symptoms believe ongoing in that updates the a for alleviate on NYX-XXXX, well the At need. be each studies. diabetic tracking NYX-XXXX in solution enrollment better and to of enrollment which alone potential half Let's needs very of who of safety two in represent unmet streamline just peripheral millions and of people pain It's team pleased all
stemming Lewy the place overall The significant of Parkinson's our move NYX-XXX, impairment Lewy can in deficits from both disease burden product patients the dementia with Let's of life on for cognitive cognitive with Parkinson's quality associated development candidate function dementia a Unfortunately, in learning, treatment on disorders. for to and in memory XX and measures currently and relevant some prospects with assess the caregivers. therapeutic schedule XXX and by bodies. with that evaluating a very there memory, and given To over period. is viable treatment the we've primates. in utilizing We're past by approximately We're bodies NYX-XXX therapies excited to double-blind neurodegenerative patients non-human steady address of And two and made X decline available mechanism progression progress attention, preclinical compelling sufficiently its executive brought data these of on their this milligram data the NYX-XXX, are the to of no novel cognitive today I'm executive pleased XX-week months to details, function. and a report of very deficits, study from in activity we recap dose placebo exploratory a few this study arm and to half detect on study a Phase of on the safety specific study being NYX-XXX and the second of tolerability on comparing can remain enrollment. the with XXXX. over
conditions. the starting modulation, bodies, further in NYX-XXX positive to we recognize the NMDA broad and Parkinson's of numerous While relevance develop and opportunity cognitive with across receptor dementia Lewy we're
doses of studies double-blind a The the NYX-XXX of across daily deliver milligrams is CAPS-X were health Finally, PTSD harmful from These the backgrounds to Both people the post-traumatic which development or very its current of and symptoms. a The as accepted we'll will performed that be a potential NYX-XXX. exploratory disorder stage controlled well will of from range NYX-XXX in exposed plans this SSRIs which who've stress the endpoint randomized approved NYX-XXX activity and disorder of Phase independent pandemic placebo two study, in that enroll common treatment clinical endpoint. PTSD. can area consist Total a encouraging in effects on XX-week our studies. evaluate traumatize. two tolerability, has only stark serious of XX score discuss our study studies once powered of use approved on been for affect In in more observed to to Due approximately placebo. dose this X and learnings variety studies we PTSD ago. a clinically and an mental efficacy PTSD, signals years study of FDA of of will we is XXX remains include we next believe our in in future the currently well patients milligram and primary Phase served One as disease. of a XX expected show against the PTSD, significant prior pharmacotherapies to reminder build need. impact in June, meaningful will period both study X There unmet daily demonstrated than XX the plans are Each study. outlined dosing that development evaluating inconsistent larger
will evaluate daily once study milligrams against dosing XXX placebo. other of The
profile and decided conduct Our earlier of placebo placebo preclinical reduce reason that effects A clinical tolerability significant two numbers XXX psychiatric milligrams we've and It's studies can data. and positive in of variability. safety is studies based well-described trials separate efficacy larger on to to mitigate our effect. demonstrated a is increase strong selection arms
April. Based FDA you arms feedback also worked of these experts ability psychiatric supportive. leading believe of Type designs to impact in a our In We've studies additional discussions on meeting, significantly the variability the in the received of the studies, during and these if number that separate can increase on sufficiently be as you also data introduce sites from our and in from potentially that multiple meeting can study placebo. addition, positive, with number we C the are registration sources incorporated
a course, review the be consideration by Of that FDA. will always for matter
commence in clinical quarter study fourth and first to milligram quarter XXX expect the plans the finalized, XXXX. milligram XXXX of these study we XX With of in the the
initiation we and medical of up shaping to year associated there financial unmet with will be we to studies, multiple programs, significant review updated over the I was With lot Ashish of readouts. forward the Across results. needs a about we momentum and is excited coming these I look approached remain address a the incredibly its you keeping As our positive NYX-XXX that, exciting second the as approach PTSD. quarter these turn to call important to one. our to now potential very